These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 15295313

  • 21. Infections associated with tumor necrosis factor-alpha antagonists.
    Rychly DJ, DiPiro JT.
    Pharmacotherapy; 2005 Sep; 25(9):1181-92. PubMed ID: 16164393
    [Abstract] [Full Text] [Related]

  • 22. Latent infection and tuberculosis disease in rheumatoid arthritis patients.
    Acevedo-Vásquez E, Ponce de León D, Gamboa-Cárdenas R.
    Rheum Dis Clin North Am; 2009 Feb; 35(1):163-81. PubMed ID: 19481003
    [Abstract] [Full Text] [Related]

  • 23. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM.
    N Engl J Med; 2001 Oct 11; 345(15):1098-104. PubMed ID: 11596589
    [Abstract] [Full Text] [Related]

  • 24. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
    De Bandt M, Sibilia J, Le Loët X, Prouzeau S, Fautrel B, Marcelli C, Boucquillard E, Siame JL, Mariette X, Club Rhumatismes et Inflammation.
    Arthritis Res Ther; 2005 Oct 11; 7(3):R545-51. PubMed ID: 15899041
    [Abstract] [Full Text] [Related]

  • 25. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
    Jung SM, Ju JH, Park MS, Kwok SK, Park KS, Kim HY, Yim HW, Park SH.
    Int J Rheum Dis; 2015 Mar 11; 18(3):323-30. PubMed ID: 25557144
    [Abstract] [Full Text] [Related]

  • 26. Recommendations to lower the risk of tuberculosis in patients treated with tumour necrosis factor alpha antagonists.
    Gómez-Reino J, Carmona L.
    Acta Reumatol Port; 2006 Mar 11; 31(3):201-3. PubMed ID: 17094331
    [No Abstract] [Full Text] [Related]

  • 27. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M, Claudepierre P.
    J Rheumatol; 2007 Feb 11; 34(2):380-5. PubMed ID: 17013997
    [Abstract] [Full Text] [Related]

  • 28. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections.
    Moiton MP, Richez C, Dumoulin C, Mehsen N, Dehais J, Schaeverbeke T.
    Clin Microbiol Infect; 2006 Dec 11; 12(12):1151-3. PubMed ID: 17121619
    [Abstract] [Full Text] [Related]

  • 29. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
    Geborek P, Bladström A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT.
    Ann Rheum Dis; 2005 May 11; 64(5):699-703. PubMed ID: 15695534
    [Abstract] [Full Text] [Related]

  • 30. Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments.
    Bieber J, Kavanaugh A.
    Rheum Dis Clin North Am; 2004 May 11; 30(2):257-70, v. PubMed ID: 15172039
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Tuberculosis screening in prescribers of anti-tumor necrosis factor therapy in the European Union.
    Smith MY, Attig B, McNamee L, Eagle T.
    Int J Tuberc Lung Dis; 2012 Sep 11; 16(9):1168-73. PubMed ID: 22794309
    [Abstract] [Full Text] [Related]

  • 33. Pulmonary infectious complications of tumor necrosis factor blockade.
    Wallis RS, Schluger NW.
    Infect Dis Clin North Am; 2010 Sep 11; 24(3):681-92. PubMed ID: 20674798
    [Abstract] [Full Text] [Related]

  • 34. Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians.
    Perlmutter A, Mittal A, Menter A.
    Br J Dermatol; 2009 Jan 11; 160(1):8-15. PubMed ID: 19016693
    [Abstract] [Full Text] [Related]

  • 35. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic.
    Keane J.
    Rheumatology (Oxford); 2005 Jun 11; 44(6):714-20. PubMed ID: 15741198
    [Abstract] [Full Text] [Related]

  • 36. Recommendations for the prevention and management of tuberculosis in patients taking infliximab.
    Salmon-Ceron D, Groupe Recherche Anti-TNF et Infections Opportunistes, Agence Française de Sécurité Sanitaire des Produits de Santé.
    Ann Med Interne (Paris); 2002 Nov 11; 153(7):429-31. PubMed ID: 12598827
    [Abstract] [Full Text] [Related]

  • 37. Biologics and infections: lessons from tumor necrosis factor blocking agents.
    Wallis RS.
    Infect Dis Clin North Am; 2011 Dec 11; 25(4):895-910. PubMed ID: 22054762
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Tuberculosis in special populations.
    Santín Cerezales M, Navas Elorza E.
    Enferm Infecc Microbiol Clin; 2011 Mar 11; 29 Suppl 1():20-5. PubMed ID: 21420563
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.